

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement appears for information purpose only and does not constitute an invitation or offer to acquire, purchase or subscribe for the securities of the Company.

*This announcement is not for distribution, directly or indirectly, in or into the United States (including its territories and possessions, any State of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The Placing Shares mentioned in this announcement have not been, and will not be, registered under the United States Securities Act of 1933 (the “**Securities Act**”).*

The Placing Shares may not be offered or sold in the United States or to, or for the account or benefit of, US persons (as such term is defined in Regulation S under the Securities Act) except pursuant to an exemption from the registration requirements of the Securities Act. There will be no public offer of securities in the United States.



Wuhan Dazhong Dental Medical Co., Ltd.

武漢大眾口腔醫療股份有限公司

(A joint stock company with limited liability incorporated in the People's Republic of China)

(Stock code: 2651)

COMPLETION OF PLACING OF NEW H SHARES UNDER GENERAL MANDATE

Placing Agent



Reference is made to the announcement of Wuhan Dazhong Dental Medical Co., Ltd. (the “**Company**”) dated June 24, 2026 in relation to the placing of new H shares under the general mandate (the “**Announcement**”). Capitalized terms used herein shall have the same meanings as those defined in the Announcement unless otherwise specified.

COMPLETION OF PLACING

The Board is pleased to announce that completion of the Placing took place on July 15, 2026. A total of 1,200,000 Placing Shares, representing approximately 6.58% of the number of issued H Shares and approximately 2.37% of the number of issued Shares as enlarged by the allotment and issue of the Placing Shares, have been successfully placed at the Placing Price of HK\$10.00 per Placing Share to not less than six Placees.

To the best of the Directors' knowledge, information and belief after having made all reasonable enquiries, (i) each of the Placees and their respective ultimate beneficial owners are third parties independent of, and not connected with, the Company and the connected persons of the Company; and (ii) none of the Placees has become a substantial shareholder (as defined under the Listing Rules) of the Company immediately after the completion of the Placing.

The Company will timely fulfil the corresponding filing procedures in respect of the Placing in accordance with the CSRC Filing Rules.

USE OF PROCEEDS FROM THE PLACING

The gross proceeds and net proceeds (after deducting placing commission and other relevant costs and expenses of the Placing) from the Placing are HK\$12.00 million and approximately HK\$11.00 million respectively, representing a net issue price of approximately HK\$9.17 per Placing Share.

As disclosed in the Announcement, the net proceeds of the Placing are anticipated to be utilised in the following manner:

- (1) Approximately HK\$3.00 million (i.e. approximately 27.27% of such net proceeds) will be applied on the expansion of its advertisement campaign on various online platform, being funding to broaden the coverage of the brand's name and image on various platforms, with engagement of both online advertising platform and physical advertising agents;
- (2) Approximately HK\$2.50 million (i.e. approximately 22.73% of such net proceeds) will be applied on the expansion of its business engagement on marketing and investor relations professionals to maintain and boost the Group's brand name among the public in Hong Kong and PRC;
- (3) Approximately HK\$2.00 million (i.e. approximately 18.18% of such net proceeds) will be used to upgrade digital diagnostic and treatment equipment within the Company's business scope, including the procurement of AI-assisted diagnostic devices, painless anesthesia systems, intraoral scanners, and other advanced diagnostic and treatment equipment, with a view to enhancing diagnostic accuracy and customer satisfaction;
- (4) Approximately HK\$2.00 million (i.e. approximately 18.18% of such net proceeds) will be applied on the upgrading of the overall dental services with standardised management and customer management system upgrades involving management system, call center, membership system development, etc.; and
- (5) The remaining balance of such net proceeds (i.e. approximately HK\$1.50 million of the net proceeds from the Placing, representing approximately 13.64% of the Placing's net proceeds) is intended to be utilised towards general working capital of the Group, including its legal and compliance cost for listed company, staff cost, rental expenses and other office overheads of the Group.

EFFECTS OF PLACING ON SHAREHOLDINGS STRUCTURE OF THE COMPANY

To the best of the Directors' knowledge, information and belief after having made all reasonable enquiries, the shareholding structure of the Company immediately before and after completion of the Placing are set out as follows:

	Immediately before the Completion		Immediately upon the Completion	
	<i>No. of Shares</i>	<i>Approximate % of the number of Shares of that class (Approximate % of the total issued Shares of our Company) (Note 3)</i>	<i>No. of Shares</i>	<i>Approximate % of the number of Shares of that class (Approximate % of the total issued Shares of our Company)</i>
Shareholders of Unlisted Shares				
Hubei Zhongshan Medical Investment Management Co., Ltd. ("Zhongshan Medical Investment") (Note 1)	31,324,102	96.82% (63.44%)	31,324,102	96.82% (61.93%)
Other Shareholders	1,028,800	3.18% (2.08%)	1,028,800	3.18% (2.03%)
Total:	32,352,902	100%	32,352,902	100%
	As at the date of this announcement		Immediately upon the Completion	
	<i>No. of Shares</i>	<i>Approximate % of the number of Shares of that class (Approximate % of the total issued Shares of our Company)</i>	<i>No. of Shares</i>	<i>Approximate % of the number of Shares of that class (Approximate % of the total issued Shares of our Company) (Note 3)</i>
Shareholders of H Shares				
Wuhan Xinglin Management Consulting Partnership (Limited Partnership) ("Wuhan Xinglin") (Note 2)	2,740,740	16.10% (5.55%)	2,740,740	15.04% (5.42%)
Public Shareholders (other than the Placees)	14,285,400	83.90% (28.93%)	14,285,400	78.38% (28.24%)
Placees	0	0	1,200,000	6.58% (2.37%)
Total:	17,026,140	100%	18,226,140	100%

Notes:

1. As at the date of this announcement, Mr. Yao Xue and Ms. Shen Hongmin held 51,300,000 shares and 36,500,000 shares in Zhongshan Medical Investment, respectively, representing approximately 44.11% and 31.38% of the equity interest in Zhongshan Medical Investment, respectively. Pursuant to an acting-in-concert agreement entered into between Mr. Yao and Ms. Shen on 3 June 2014, Mr. Yao and Ms. Shen agreed to act in concert in respect of their voting rights in Zhongshan Medical Investment. Therefore, each of them was deemed to be interested in the equity interest in Zhongshan Medical Investment held by each other by virtue of the SFO.
2. As at the date of this announcement, Yao Qi was the general partner of Wuhan Xinglin. Therefore, Yao Qi was deemed to be interested in the Shares directly held by Wuhan Xinglin by virtue of the SFO.
3. The aggregate of the percentage figures in the table above may not add up to the relevant subtotal or total percentage figures shown due to rounding of the percentage figures to two decimal places.

USE OF PROCEEDS FROM THE GLOBAL OFFERING

The H Shares of the Company were listed on the main board of the Stock Exchange on July 9, 2025 (the “**Global Offering**”).

A total of 10,861,800 H Shares were issued at an offer price of HK\$20 per Share, with gross proceeds of approximately HK\$217.24 million. After deduction of related expenses, the net proceeds from the Global Offering were approximately HK\$178.17 million (the “**IPO Net Proceeds**”).

As at the date of this announcement, the intended use of the IPO Net Proceeds is consistent with that previously disclosed in the annual report of the Company for the financial year ended December 31, 2025. The following table sets out the utilization of the IPO Net Proceeds as at the date of this announcement:

Intended use of Net Proceeds	Approximate percentage of Net Proceeds	Planned amount of Net Proceeds to be used (approximately HK\$ million)	Utilized Net Proceeds up to December 31, 2025 (approximately HK\$ million)	Unutilized Net Proceeds up to December 31, 2025 (approximately HK\$ million)	Expected timeline for full utilization of the remaining Net Proceeds ⁽¹⁾
Establishing new dental institutions	35%	62.36	0.92	61.44	By 31 December 2029
Acquiring dental institutions	25%	44.54	0.00	44.54	By 31 December 2029
Upgrading and renovating some of our existing dental institutions	10%	17.82	3.74	14.08	By 31 December 2029
Optimizing our information technology infrastructure and information technology systems	10%	17.82	1.62	16.20	By 31 December 2029
Developing our medical professional team	10%	17.82	7.70	10.12	By 31 December 2029
Working capital and general corporate purposes	10%	17.82	4.79	13.03	By 31 December 2029
Total⁽²⁾	100%	178.17	18.77	159.40	

Notes:

- (1) The expected timeline for full utilization of the remaining Net Proceeds set out in the table above is based on the Group's best estimate of the future market conditions, which may be subject to change as a result of the development in current and future market conditions.
- (2) Totals may not be the exact sum of numbers shown here due to rounding.

By order of the Board
Wuhan Dazhong Dental Medical Co., Ltd.
Mr. Yao Xue
Executive Director and Chairman

Wuhan, Hubei Province, PRC
July 15, 2026

As at the date of this announcement, the Board of the Company comprises: (i) Mr. Yao Xue, Ms. Shen Hongmin, Mr. Guo Jiaping and Ms. Liu Hongchan as executive directors; and (ii) Mr. Shu Yijie, Ms. Huang Suzhen and Mr. Xie Dong as independent non-executive directors.